Combination treatment for KRAS-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of drugs for people with advanced lung cancer that has a specific genetic change called KRAS. The treatment aims to shrink tumors or slow their growth after standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced non-small cell lung cancer that cannot be removed with surgery.
- Your cancer must have a KRAS gene mutation.
- You must have tried at least one standard treatment that did not work or caused severe side effects.
- You must be generally well enough to care for yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with advanced pancreatic or colorectal cancer that has a specific genetic change called a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial studies a combination of two targeted drugs (tunlametinib and fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and who have already tried at least two other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.